Company Introduction

C4U Corporation is a biotechnology venture company founded in May 2018, by Dr. Tomoji Mashimo (currently Professor of University of Tokyo) et al.
We have developed proprietary gene editing techniques such as one using CRISPR-Cas3 that is characterized by its unprecedentedly high target sequence specificity (no off-target, namely, safety in medical term) and large scale deletion (efficient knock-out). We are looking for alliance partners to develop innovative products and licensees who would utilize CRISPR-Cas3 technology.

Brief description of main products or services 

C4U’s technology：Gene editing technology, especially CRISPR-Cas3, that is invented by Prof. Tomoji Mashimo et al. and has useful features suitable for gene therapy, CRISPR Diagnostic and biotech researches.

CRISPR-Cas3 technology can be utilized in various market, but our main targets are medical, agriculture and industry area.

Medical field is a primary area where CRISPR-Cas3 technologies are expected for practical application. It is expected that by editing genes of human cells, novel gene therapy technologies cure the patients who are suffering from serious illness caused by genetic disorders.

C4U have a kind of hybrid commercialization strategy for the development of novel gene therapies using CRISPR Cas3 technology. A part of our pipelines should be pursued by C4U and others would be developed through collaborations with pharmaceutical companies.

In other area such as agriculture and industry, C4U aims to conduct the collaborative research or license the technology for further application.